Luciano Rossetti, MD | Authors


Dr. Luciano Rossetti on the Function of Anti-PD-L1 Treatments in Bladder Cancer

November 18, 2015

Luciano Rossetti, MD, head of Global Scientific Strategy, Merck Research Laboratories, talks about the discovery of PD-L1 and how the finding has evolved into potential treatments for bladder cancer patients, specifically avelumab.